Nuon Therapeutics Inc. Announces Data Demonstrating Uric Acid Lowering Activity of Tranilast to Be Presented at EULAR 2010

Published: Jun 03, 2010

SAN MATEO, Calif.--(BUSINESS WIRE)--Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that two scientific abstracts on the activity of tranilast against key components of gout – high serum uric acid levels and monosodium urate crystal-induced inflammation – have been accepted for The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology, to be held in Rome, Italy, June 16-19, 2010.

Back to news